The management and survival of patients with advanced germ-cell tumours: improving outcome in intermediate and poor prognosis patients

N Bhala, J M Coleman, C R Radstone, J M Horsman, Jacob George, B W Hancock, M Q Hatton, R E Coleman

    Research output: Contribution to journalArticlepeer-review

    17 Citations (Scopus)

    Abstract

    The survival of germ-cell tumours (GCT) was transformed after the introduction of cisplatin-based therapy. Previous trials have indicated BEP (bleomycin, etoposide and cisplatin) as the optimum treatment, although some centres including our own advocate the use of the alternating regimen POMB-ACE (cisplatin, vincristine, methotrexate, bleomycin and dactinomycin, cyclophosphamide and etoposide) for men with intermediate or poor prognosis disease. We analysed the survival and management of GCT patients treated at a specialist cancer centre in relation to internationally recognised prognostic groupings.
    Original languageEnglish
    Pages (from-to)40-47
    Number of pages8
    JournalClinical Oncology
    Volume16
    Issue number1
    DOIs
    Publication statusPublished - 2004

    Fingerprint Dive into the research topics of 'The management and survival of patients with advanced germ-cell tumours: improving outcome in intermediate and poor prognosis patients'. Together they form a unique fingerprint.

    Cite this